These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 23680817)

  • 21. Predicting 6-week treatment response to escitalopram pharmacotherapy in late-life major depressive disorder.
    Saghafi R; Brown C; Butters MA; Cyranowski J; Dew MA; Frank E; Gildengers A; Karp JF; Lenze EJ; Lotrich F; Martire L; Mazumdar S; Miller MD; Mulsant BH; Weber E; Whyte E; Morse J; Stack J; Houck PR; Bensasi S; Reynolds CF
    Int J Geriatr Psychiatry; 2007 Nov; 22(11):1141-6. PubMed ID: 17486678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of Recurrence After Recovery From a Major Depressive Episode With Antidepressant Medication Alone or in Combination With Cognitive Behavioral Therapy: Phase 2 of a 2-Phase Randomized Clinical Trial.
    DeRubeis RJ; Zajecka J; Shelton RC; Amsterdam JD; Fawcett J; Xu C; Young PR; Gallop R; Hollon SD
    JAMA Psychiatry; 2020 Mar; 77(3):237-245. PubMed ID: 31799993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physical exercise augmented cognitive behaviour therapy for older adults with generalised anxiety disorder (PEXACOG): study protocol for a randomized controlled trial.
    Stavestrand SH; Sirevåg K; Nordhus IH; Sjøbø T; Endal TB; Nordahl HM; Specht K; Hammar Å; Halmøy A; Martinsen EW; Andersson E; Hjelmervik H; Mohlman J; Thayer JF; Hovland A
    Trials; 2019 Mar; 20(1):174. PubMed ID: 30885256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study.
    Papakostas GI; Fava M; Baer L; Swee MB; Jaeger A; Bobo WV; Shelton RC
    Am J Psychiatry; 2015 Dec; 172(12):1251-8. PubMed ID: 26085041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 24- and 36-week outcomes for the Child/Adolescent Anxiety Multimodal Study (CAMS).
    Piacentini J; Bennett S; Compton SN; Kendall PC; Birmaher B; Albano AM; March J; Sherrill J; Sakolsky D; Ginsburg G; Rynn M; Bergman RL; Gosch E; Waslick B; Iyengar S; McCracken J; Walkup J
    J Am Acad Child Adolesc Psychiatry; 2014 Mar; 53(3):297-310. PubMed ID: 24565357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Generalised anxiety disorder in elderly patients : epidemiology, diagnosis and treatment options.
    Flint AJ
    Drugs Aging; 2005; 22(2):101-14. PubMed ID: 15733018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Escitalopram versus placebo in the treatment of dysthymic disorder.
    Hellerstein DJ; Batchelder ST; Hyler S; Arnaout B; Toba C; Benga I; Gangure D
    Int Clin Psychopharmacol; 2010 May; 25(3):143-8. PubMed ID: 21811192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Escitalopram continuation treatment prevents relapse of depressive episodes.
    Rapaport MH; Bose A; Zheng H
    J Clin Psychiatry; 2004 Jan; 65(1):44-9. PubMed ID: 14744167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.
    Soares CN; Thase ME; Clayton A; Guico-Pabia CJ; Focht K; Jiang Q; Kornstein SG; Ninan PT; Kane CP
    CNS Drugs; 2011 Mar; 25(3):227-38. PubMed ID: 21323394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treating late-life generalized anxiety disorder in primary care: an effectiveness pilot study.
    Calleo JS; Bush AL; Cully JA; Wilson NL; Kraus-Schuman C; Rhoades HM; Novy DM; Masozera N; Williams S; Horsfield M; Kunik ME; Stanley MA
    J Nerv Ment Dis; 2013 May; 201(5):414-20. PubMed ID: 23588228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of combined pharmacotherapy and psychotherapy for improving work functioning in major depressive disorder.
    Lam RW; Parikh SV; Ramasubbu R; Michalak EE; Tam EM; Axler A; Yatham LN; Kennedy SH; Manjunath CV
    Br J Psychiatry; 2013 Nov; 203(5):358-65. PubMed ID: 24029535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pilot controlled trial of bupropion XL versus escitalopram in generalized anxiety disorder.
    Bystritsky A; Kerwin L; Feusner JD; Vapnik T
    Psychopharmacol Bull; 2008; 41(1):46-51. PubMed ID: 18362870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized controlled trial of cognitive-behavioral therapy for generalized anxiety disorder with integrated techniques from emotion-focused and interpersonal therapies.
    Newman MG; Castonguay LG; Borkovec TD; Fisher AJ; Boswell JF; Szkodny LE; Nordberg SS
    J Consult Clin Psychol; 2011 Apr; 79(2):171-81. PubMed ID: 21443321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cognitive Behavioral Insomnia Therapy for Those With Insomnia and Depression: A Randomized Controlled Clinical Trial.
    Carney CE; Edinger JD; Kuchibhatla M; Lachowski AM; Bogouslavsky O; Krystal AD; Shapiro CM
    Sleep; 2017 Apr; 40(4):. PubMed ID: 28199710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized controlled trial of telephone-delivered cognitive-behavioral therapy for late-life anxiety disorders.
    Brenes GA; Miller ME; Williamson JD; McCall WV; Knudson M; Stanley MA
    Am J Geriatr Psychiatry; 2012 Aug; 20(8):707-16. PubMed ID: 22828172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adult attachment as a moderator of treatment outcome for generalized anxiety disorder: Comparison between cognitive-behavioral therapy (CBT) plus supportive listening and CBT plus interpersonal and emotional processing therapy.
    Newman MG; Castonguay LG; Jacobson NC; Moore GA
    J Consult Clin Psychol; 2015 Oct; 83(5):915-925. PubMed ID: 26052875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study].
    Chauvet-Gélinier JC
    Encephale; 2010 Oct; 36(5):425-32. PubMed ID: 21035633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. D-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder.
    Hofmann SG; Smits JA; Rosenfield D; Simon N; Otto MW; Meuret AE; Marques L; Fang A; Tart C; Pollack MH
    Am J Psychiatry; 2013 Jul; 170(7):751-8. PubMed ID: 23599046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trial of Electrical Direct-Current Therapy versus Escitalopram for Depression.
    Brunoni AR; Moffa AH; Sampaio-Junior B; Borrione L; Moreno ML; Fernandes RA; Veronezi BP; Nogueira BS; Aparicio LVM; Razza LB; Chamorro R; Tort LC; Fraguas R; Lotufo PA; Gattaz WF; Fregni F; Benseñor IM;
    N Engl J Med; 2017 Jun; 376(26):2523-2533. PubMed ID: 28657871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Similar changes in cognitions following cognitive-behavioral therapy or escitalopram for major depressive disorder: Implications for mechanisms of change.
    Farabaugh A; Fisher L; Nyer M; Holt D; Cohen M; Baer L; Shapero BG; Huz I; Cardoos A; Fava M; Alpert JE
    Ann Clin Psychiatry; 2015 May; 27(2):118-26. PubMed ID: 25954938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.